Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Dana Lynch, Aurinia's Director of Corporate Communications and Corporate Affairs. you. Thank

begin. may You

Dana Lynch

and Aurinia's all year-end XXXX Melissa, call financial joining to discuss fourth thank you, for you today's results. Thank quarter and

for CEO; of Colao, Financial Medical available this Q&A Joe the members leading Solomons, the of me morning Chief team, Peter Officer, our Officer; Other President Joining at call. specifically, and executive Max Neil are the call. be Miller, Commercial of the who Officer, and Chief presentation the will Chief conclusion be will portion Greenleaf, and Dr.

This morning, press Report release filed financial our on operational announcing Annual recent highlights we issued our a results and Form XX-K. and

our Exchange For more also our are to the www.auriniapharma.com. U.S. on filings Commission, refer which Securities and information, available please at with website

make expectations. forward-looking our differ to may on uncertainties, risks subject are may we These statements number our based current of a significant materially. and and statements call, this results forward-looking actual During

of please our Report Exchange financial XX-K, Canadian could with discussion our and Annual with affect on a the that U.S. Securities press the and filings Commission Securities future our of all to in refer along Authorities. our factors release For business, recent Form and and results disclosures

update XX, are based required statements by current noted otherwise this note such as Except currently we at today's any time. the Please statements. today, available February law, that no information made are during XXXX, upon as all call to obligation unless of and to assume us

and Peter me now call Let Greenleaf. Peter? Aurinia's the to CEO, turn over President

Peter Greenleaf

we operational every part a joining achieved today. company, was Across year to transformational for for everyone Dana, the and Aurinia. milestones. major strategic thanks us and Thanks, of XXXX

become company. a evolved from small capabilities with development revenue-producing biopharmaceutical With integrated limited fully drug these achievements, a company being we to

strictly the nephritis, start serious over in life-threatening year, care cash shifted superior utilization We and And disease, a lupus for to product. and U.S. in health and clinical the that, received by results community. ability treat standard to first our jumped now professionals launching generation approval immediately current the of demonstrating with To rare FDA and into cash from we commercial LUPKYNIS care. the patients we serve

In of application the partner, Agency. our major patients globalizing key our with another ability step the furthering European marketing approval This U.S. for hit June, our filing milestone business authorization serve voclosporin was a in Medicines of Otsuka, we a with to beyond the in and alongside

as that ongoing establish To paramount recognize to clinical in therapy. generation its establishing the well of data nephritis, our leadership and driving is lupus we duration as adoption, evidence LUPKYNIS

June last in pivotal results pivotal unveiled of published year, Lancet of including positive now is only for also data. LUPKYNIS years nephritis the medicine FDA-approved AURORA first with and the In three LUPKYNIS lupus of continuation results, long-term the registrational December, X and safety the study. trial the study, we

X of it information long-term will in to our filed important be in of prescribers supplementing post-marketing of data, the be with We assessing EMA, filed package we believe AURORA our the commitments additional nephritis. submitted of will also using already treatment to to in half this lupus added will benefits MAA. in our The results connection and the LUPKYNIS first year, and being be to this the submitted the FDA

compounds. first the the with took we new of XXXX and acquisition Finally, our innovation big driving in towards preclinical diversifying step pipeline two

now biopharma diversified out well capabilities and our integrated With medicine research, addition to forward a single-asset from of translational have development, we these as assets, organization. a company building in the as process moved

future that will, autoimmune in growth. by I'm puts strength I'm to position of serve disease. a year major a In in confident to work this of proud us of our impacted this team's the most accomplishments drive milestones, vision realizing in rare patients progress,

update to on on, our provide move give of then With a our efforts followed anticipated status first, preview and going LUPKYNIS provide for year fourth outlook that, quarter of for voclosporin. and our by on with all this I'll guidance. further our full results, XXXX context, detail to business now revenue And commercial globalization an milestones. touch pipeline I'll our also the I'm

Finally, I'll financial up our all roll and position. current review that

XXXX million million, business So prior with an where generated is the sales, to we let's from right which the quarter, of revenue on begin of for with fourth our representing quarter, the total performance U.S. recognized we increase launch relative LUPKYNIS. XX% In to net for $XX.X target guided XXXX. $XX.X bringing in

team, the results, impact results and commercial launched are built of considering and our especially strong achieved we pleased pandemic. We of unprecedented and the global unpredictability COVID-XX with product our all these very these managing while ongoing

launch Our impact multiple improve dimensions. to and across commercial metrics continue

In PSF added of new forms, we total patient with the prior months and XXX over showed notable growth year ending patient start November The quarter. X,XXX QX, start October forms. the

of variant our While to did as impact PSF, a universe. in patient and COVID December, we see prescriber the started Omicron slowdown

we moving conversion addition, In PSFs PSF excess XX%. patients are in on XX-day see therapy. to in to of continue now progress rates

on in also month. both and We XX track XX-day ongoing improvements are each with conversion rates

team begin to efforts U.S. access team patient possible. On making our improvement develop coverage confirmed and reflects policies more Aurinia total efforts as our that as ensure great of lives. of treatment the patient the we payers headway. has and and LUPKYNIS through that patients quickly roughly working access to support personalized LUPKYNIS access are with represent patient XX% specific can the This plans payers to front, of notable

patients unfortunately, begin patients discontinuations. course, expect some Of as and with LUPKYNIS, can treatment we more to see more

trends to early in discontinuations our While aligned about tracked far, rates, we significant what clinical is statistically drop-off which to XX% trials, XX%. it's too with are still in thus see overall

three patient in patients adherence to on to XXXX. between treatment LUPKYNIS, adherence in patients trends. with Obviously, too, six only rates. been these understand most it we LUPKYNIS will look at more overall months, of to Remember, early started too and so When emerging is we time the QX need treatment mid-QX have drug on cases, emerging here, cite

more our resource, support As on education, adherence to to treatment we Aurinia with partners and direct-to-consumer overall will and lupus of to continuity Alliance, we care. improve the nephritis patients patient and continue provide patient and work persistence, to their personalized tools information and activities their support ensure to our advocacy gather adhere through

we the look at pharma XXXX, calendar experienced When specialty year. most we far, of same circumstances have, that at thus the worked other through the companies beginning

last when has Omicron impacted policies significantly at course, base and pandemic, off And patient access start the insurance employer-covered in and their These to resets patients second of the can things treatment the impact our continuity overall getting PSFs in date, patient of since This first and numbers care. continues to a strong and slow our and start year, launch point year. the year. to down or to with the Changes through COVID is our medications X,XXX overall coupled early the refilling during and results week. reflected of carriers start variant, in slowdown particular, to co-pay

that that We continue XXXX, to delivered quarter growth commercial have on drive in quarter-over-quarter -- and execute growth. capabilities confidence our and we will

$XXX LUPKYNIS range on in to challenges guidance spite in revenue and sales setting of to in of in we be strong seeing range QX, QX, Building momentum million for the saw are we're of year from challenging year-over-year the as the we which in fiscal currently in revenue, of the aggressive of we the for environment increase an growth This XXX% facing. XXX% of XXXX. light more million see $XXX we're represents to than

ensuring confident on patients are achieve We results conversion and treatment. by can new driving we patient seamless these of prescriptions and efficient starts to

in or manufacturing include ex-US does market revenue voclosporin payments, anticipated not guidance Japan. with or to related and milestone royalty Our European agreement the Union our licensing Otsuka to sales

up -- label well low As a Aurinia favorability and double-digit upon double-digit royalties $XX reminder, contingent to the EMA royalties cost supply will through on million upon the as of cost-plus receive arrangement. recovery a approved as sales approval,

of reported Europe authorization previously, approval them. includes the with posed and well the Otsuka working our in standard Medicines submission with answers the we closely as most data by June AURORA to European marketing X questions Agency our application recent support This we're to XXXX, as process. As XXX-day sharing filed of in

been process we to of as the half that expected, along pleased are EMA expect moving the We second XXXX. has approval in continue and

we're Let's development at here now shift work gears to Aurinia. research doing and

December, at a XX months additional in to period and a submit X year as AURORA this Data of of positive with from peer which at major as scientific reinforces XXXX. results plan X review study. LUPKYNIS for for conferences the we presentations for submissions treatment, three-year the XXX the XXXX first as safety manuscript original in comparable efficacy. half to that publication on patients over throughout abstract the looked continuing risk-benefit sustained mentioned, We favorable an in I've as this study of As final well of AURORA seen well from study, continuation reported the X AURORA profile

professionals, further safely LUPKYNIS patients support All payers and therapy. should activity of of healthcare this beyond provide to continue one-year for treatment

work year you, clinical patients ENLIGHT-LN study of collected The patient gained US this knowledge be sites we will in XX to LUPKYNIS for this recruitment To the with the trial the patients remind the aim up REGISTRY. setup and pediatric vocal Other of study into initiate continued to the as ongoing clinicians therapy. and payers shared be to and improve registry care for from study and we access data sites insights LUPKYNIS. ensure with this to then plan would and to gain further real-world about to well leverage

AURXXX, and compounds work we continues drive and to both to for XXXX. submit team assets, AURXXX plan pipeline in on Our research INDs IND-enabling our

achieved, As a build-out $XXX in on this that no our work balance happy next the investments and pipeline to to and operate healthy all hand cash we of debt. sheet, equivalents are with for you outstanding the these including of can continue report approximately imagine, I'm million steps important of future.

LUPKYNIS, the cash incoming the our next strength sheet and fund we flows our few can years. the balance from for business of With

and financials. at end over to any now have. questions for might to Miller turn to return you Joe? will on the I in the call our more answer I'll of call these Joe also recap activities detail the

Joe Miller

Thank you, morning, Peter, and good everyone.

cash by company's to of ATM the from XX, $XXX.X from offering, million support had due LUPKYNIS the the million spend warrants, to investments proceeds and infrastructure stated, previously primarily of equivalents December of XXXX. increase December launch The $XXX.X Peter offset and receipts cash receipt compared to XXXX, of XX, was proceeds of and cash As commercial the from Aurinia of the as cash sale exercise at options LUPKYNIS. stock and net the

license includes part dedicated build our payments It and AURXXX. an manufacturing upfront upfront our programs, payment Lonza and with AURXXX recently and for of monoplant for to capability also developmental agreement as our made collaboration related to acquired payment a inventory

the its beginning in back-office infrastructure. and phase the company of and LUPKYNIS commercial FDA year, in in out of prior only reminder, was was phase a the As pre-approval the still building

$XX.XX. of The raised the the ATM has in sales early, net will mentioned fourth no There terminated million Regarding quarter this company today. ATM price of $XXX.X be ATM. of an at as the we proceeds effective more under average

funding current in that years. our believe have supporting to and supply, include FDA-related business fund investing manufacturing financial development at we operating commitments, least planned sufficient executing our plans, our commercial our and strategy packaging post-approval and conducting including programs, development for activities of activities, commercial We on funding funding the infrastructure, few resources pipeline, research commercial drug which our next

agreement was for XXXX, for revenue for approval $XX.X December quarter commercial sale resulting quarter the net in million an for ended million quarters from primarily net net of $XX of XX, The revenue million, primarily LUPKYNIS ended million XXXX, XXXX, the respectively. XX, of Otsuka million from December ended FDA December December the December entering January was of XX, with and Total XXXX, XXXX, year consisted into ended revenue ended the was year upfront XXXX. $XX to revenue following due payment XX, $XX.X XX, and them. collaboration $XX.X respectively. Total our Total years and and XXXX, and and

sales any not sale sales not and and associated upfront and ended years approved for of with of for have December December $X.X of payment and December XX, XXXX, Cost the respectively. In XXXX XX, million the $XXX,XXX quarters from XXXX, commercial zero Cost the respectively. XX, and did it. the zero ended have drugs company Otsuka were did XXXX, sales XX, cost were for December XXXX,

Gross SG&A December XXXX, margins million December XXXX, months for XXXX, $XX.X ended ended and the and were $XX.X was December XX administrative, approximately the XX, million quarters X general for and XX, respectively. XX%. expenses XX, and Selling,

was due SG&A For million $XX trade The Also the to of for increase XXXX. to shows the was contributing the ramped XXXX, in and and and sales with in support commercialization administrative the functions occurring the million, an and expenses LUPKYNIS, XXXX, increase years increase and were commercial expansion launch sponsorships of activity December travel, periods XXXX. up which an third of quarter during ended throughout associated costs connected respectively. $XXX.X both XX, to employee-related

million ended respectively. expenses compensation December share-based and XX, SG&A and Non-cash XX, was XXXX, quarters for the XXXX, $X.X December $X.X million

For XXXX, the $XX.X respectively. compensation years SG&A ended December million XX, and was expense $XX.X share-based XXXX, non-cash million, and

and ended decrease approval $XX.X the For December the of research certain due late quarters were the driver to development certain The the of termination to in decrease million. allocation XXXX, costs employee-related XX, in primary and and XXXX, expenses December $XX.X was due post-FDA XX, XXXX. million costs for the programs to SG&A and

years XX, $XX.X R&D respectively. million XXXX, million, the XX, were For ended and December expenses and December XXXX, $XX.X

offset expenses development acquired programs, to LUPKYNIS. and a programs, expenses voclosporin were an AURXXX following upfront primary increase by approval developmental higher to research related accrued and organization to The the drivers license costs for new AURXXX, in due its our the and clinical milestone recently decrease related clinical of

$X.X share-based sorry, compensation December for XXXX and the XX, quarters December was December million R&D XXXX, ended XXXX, the XX, quarters and and for respectively. $XXX,XXX – expense Non-cash XX, XX, December ended I'm XXXX,

ended For $X.X and million million, and XXXX, respectively. XX, was share-based compensation the expense December R&D-related $X.X XXXX, non-cash years

$XX.X reported XXXX. For common of quarter the quarters compared for loss million, XX, loss XXXX, per loss per common million share $X.XX as December or or ended $X.XX loss a net net XX, of net share December $X.X ended net the a to Aurinia

million net per XX, as $X.XX years of loss a net $XXX.X reported for the million share the common net net $X.XX or of loss share a For $XXX or per December loss to previous period. ended Aurinia XXXX, compared loss common

would I hand for like Peter that, call over to to With closing Peter? remarks. the back some

Peter Greenleaf

Thanks, Joe.

safe growing serving to to to of delivering call, commitment years a continued the come. throughout a treatment patients XXXX, patient mission As company you to heard and effective our the needs profound made in a with high and population impact our ensure for underserved

everyone microphone the to I joining your want to thank again us today. open questions. for up We'll now

Operator

question first the line Our Alethia question. of with Instructions] [Operator proceed Young Fitzgerald. your you. Thank Cantor with comes from Please

Alethia Young

one Hey guys. and maybe just Thanks for taking Maybe my question. X.X.

launch over what the year And talk can the on seeing. in? be that COVID-XX you XX impacts a with cadence then than you months characterize to first are factoring what Do you what's of you. could expect sustained Thank Just the also, how kind more seen little about versus of these you're year? it that maybe you're potential different just impacts the bit going you have of in may last been Omicron? Is

Peter Greenleaf

and Thanks, Alethia, appreciate the question.

quarter-on-quarter which in weeks impact, had And things most So patients we the clear January, improve. cetera. of having insurance the plan into variant way of see couple we do changes, then on et -- try we course, copay pretty top because there seeing we're not start pharma to that, the Omicron be which resets, impact call that starting December of of and we're last impact of but space, typical like the specialty like the guidance, out in of year the giving any to company

think this variant I our hope drugs think space basis, but be giving to February this then guidance, period start in every year-on-year a respect ways, any today. with business, and impact, company for marketing just our selling early time We like guidance. impact the not quarterly on guess, that's January, it annual in And So continuing is will would Omicron to will there's two I a about I lessen.

year. a first of So quarter impacted if gating a QX pattern I then it getting back QX the through standpoint, thinking and being into growth about healthy from were we to the anticipate

Alethia Young

Okay. gotten already. And this to because I've question just clarify

things first besides but payer quarter, like dynamics for are there that trends the that You like this still you that underlying? growth COVID highlighted trends and you've the guys The the feel in launch begins feel the product and are confident about [ph]?

Peter Greenleaf

That's correct.

Alethia Young

you, Thank guys. Awesome.

Peter Greenleaf

Alethia. Thanks,

Operator

you. Thank

Please Our next proceed line question. the Maury your comes from of Jefferies. question with with Raycroft

Maury Raycroft

some challenges, compared if discontinuation saw what issues Hi, in a and just you're these and about clinical you that? the more And morning about about talked taking for doing your little if and talk more good questions. around to of adherence more year. managing thanks planning studies? my and this you provide was throughout for reasons XXXX you bit on you talk I how specifics could how assumptions for wondering can how Can you

Peter Greenleaf

Sure.

not we've would it's discontinuing and be the underscore as that reasons Board. getting patients would It's So I right the and seen. adherence, What -- try one come host reasons product, payer been discontinuations the is, are I on paying to their of not the different not why of you we're the range now. across payer the to That's kind related. from tell like across they're might ones that is PSFs then to not for in But a board on a drug. of host in

we Asian primarily from look we're just trying as can population which that's prescriptions, out Remember, to a with challenge we in more. analogs U.S., and longer-term population to a and other an flesh population female to states are adherence up picking to in not general. Everything patients disease tolerability with Hispanic compliance the that African-American, are that understand dealing patient and

of to we're persistency think looks really the So third we're we'll and six report the more potentially steer where one a like, looking when are we going. have majority of since there. where some and the patients fourth have at really adherence on and this side, especially But quarter would persistency, we the in be of characterization guidance said, long-term gone what we don't as out I three it and this year on on data, provide And closely. months good

clinical our trials. So what And saw much it Maury. the board, pretty to in it's we across maps

Maury Raycroft

it. Got

comment in filed I'm particular IPR positioning IP and wondering you Okay. patent. an that just can on your this just your against XXX issue? latest also maybe And Sun if And thoughts you XX-K, on your note quick question,

Peter Greenleaf

Sure. notice We filed that claims let dosing patent an partes has clinical actually with want receive minute protocol inter lupus our take review, thank being trials. February I question. me LUPKYNIS to address of you our to one. at the to in on And a respect petition nephritis this directed did for IPR, or XX for used

As full December may a a recall, who was out At to that that stage, talk patent of as petition IPR for a really our preliminary infringement was a a a just too all recall, I'll give this XXXX. term are -- matter, it's which to separate has filed extending assessment position of you this from in about reading been in Sun Pharmaceuticals if you've Ks, patent suing you received. really we second, all

we're So This patents. and our review, mentioned in as at process it, significant Patent prosecute had we're looking the patent Office to our being at U.S. before in but all we've valid as approved challenges particular, We're confident previously putting by defend office. reply. And said bring our any actual I've other before, we patent any to challenge again, vigorously patent being together this that get, and patents. our that party from we'll as Trade

action With to commenced under actually solution. claim patents affiliates, I of our to relating December Sun of and Jersey relating voclosporin's mentioned, ophthalmic and of as Sun in is ophthalmic we and just product, that laws an the we the disclosed U.S. expiration in a arising which for Sun's respect C&I immunosuppressant is solution in has patent summary, to their CEQUA against patent prior to on infringement with the XXXX, our a XX-K, New in District the certain U.S. been separate have Court, litigation action

manufacturing, responded and and and Sun or lawyers initial patents relief, basically, CEQUA of our in here construction, March pleadings Trial those exchanged Obviously, qualify action this using and the the denying one confirming monetary have is what or all patents on that XXXX. of Sun Sun patent process in actually that's disclosures, has selling preventing We including asserting and has we're infringement infringed as by on order action, an form somewhere around claim Sun and in probably ongoing. are the valid. we for that costs. requested of So injunction and/or relief

the gives litigation the of that and mentioned on side Sun So backgrounder equation. previously the IPR full the

Maury Raycroft

Got it.

my for Thanks helpful. Okay. That’s questions. taking

Peter Greenleaf

Thanks, Maury.

Operator

you. Thank

with Our next question. your the line comes proceed Please Schwartz SVB from Securities. of question with Joseph

Joseph Schwartz

think, much. understand that and help like than issue to conference, of aggressive had a or healthcare if Peter, assumptions what LUPKYNIS guidance at underlying things in patient there And for Thanks on forms, aggressive I aggressive aspects guidance start either our Hi. plans conversion are main more very could couple ago you you've times rates or been was basis XXXX terms weeks to an of and shared seeing? this of wondering then some us the discontinuations, you others? relative particular absolute your guidance. I Are revenue revenue

Peter Greenleaf

me let Well, in and underscored start today. Yeah. there, it I call our

the to offices, guiding everyone comments is variant, XXX business my in of doubling to in that patients today. year-on-year XXX-plus companies for Omicron the aggressive. the comments challenges challenges the my of are, the more for it's cetera. than I its companies given think, percent I the aggressive in our growth our into -- that I themselves, that think light up reps, our doubling year growth area. facing individual and was the context et is and start context impact kind with the on think conference, And going year-on-year And of is Most

don't or us gates an for the around the getting how adherence year, back quarter, PSF give obviously, how quarter-on-quarter growth of -- start currently. level prescription to maintaining forms in terms what what at for think getting to underlies we achieving but the we're about significant In first numbers seeing is guidance, to forecast and after these

again, XX% XX% somewhere our to trials. coming of out clinical around as seen So we estimated, we've that that

drug, been those sort to all But factors, In good hold what on time. as -- how have we qualify and seen to I what persistency Joe. addition, to it's respect have hard But to long of see we are over it's we've with already of said patients to. earlier, I think need

Joseph Schwartz

approval, a that maybe just this the EU hopefully, quick later for on if And Thanks Okay. housekeeping color. question, year. could, I

label, $XX stand million with million. I determine that would was on share to understand -- the to more depends come I and range us the at as factors Can of you or you milestones wondering out the of that think on higher kind milestone is you range? gain low-end what any the color $XX it. of I that whether

Peter Greenleaf

range. to can feel get a we'll lower really end Yeah, with X know we continuation et actually we this comments you feel back $XX end of that's that come in we back that Europe, of We a to are length very the on constrained that confident try for year. came is a obviously, the might the because such of what oversimplify more approval, study see I'll of the get we But confident we the it. which half if the label were in the cetera, million. get full you be of If other that US, areas as therapy, similar those that XXX-day in should never upper until AURORA targeted way that. There

Joseph Schwartz

much help. the Excellent. Thanks very for

Peter Greenleaf

Thanks, Joe.

Operator

you. Thank

Cowen with from Stacy your Company. Please Ku of proceed with Our the question. comes next line and question

Stacy Ku

for morning. Good Thanks taking questions. our

per the pricing net pricing for consistent provided with thinking apply would the enrollment LUPKYNIS. we much As forms the -- placeholder about How we stay that QX to around So pricing have initial and the conversion, it is around one our annually. better be of pricing patient net than QX? we metrics $XX,XXX you should

closer getting our math, to in we're $XXX,XXX. rough So

drop and see to you. QX of forms And conversion your commentary, any would So as enrollment expect given think to related to about we given significantly the do down this pricing the question, all be potentially guidance also from Thank QX? we stronger appreciated.

Peter Greenleaf

dose of aligns adjustments previous we So this we monthly is what the more but estimate pricing, my or start commentary Street and we that number right? giving let to of vary, per length know patient could average $XX,XXX of the Until like basis, over on on And patient, a look On guidance the sort with going quarterly importantly, are really is therapy look to with me not hard it's first. give how net going to in previous to the confidence reason maintained higher. almost that is persistency. not it the directly net the average a

is that you net net confident that tell sort total of is not it commented above breaking cetera, because can that we're of swing where stay seems number we can or now We've should those like et $XX,XXX around. down patients estimate And right throughout. our on on consistent therapy, What tracking. numbers versus we're

and quarter year. how we first quarters of question the rest of versus that should be thinking Lastly, your forms start of on the patient

As said that we're I say, I see estimate and previous giving we softness start would we questions, it's quarter to first think to quarterly patient trends guidance, pickup not forms move right obviously, a those see while And in safe the to to rest feel in in year. are starting that the of we're start QX, forms, and a need confident patient QX for to that move and as we into we QX the in the going direction.

Stacy Ku

you. Thank

Operator

you. Thank

Wainwright. the Ed proceed H.C. from Arce with comes your of Our Please with next line question. question

Ed Arce

my on questions end congrats taking for a thanks A of Hi, couple and for me. of strong questions year. the

key further well believe you First, said, sales coverage given, what as some to the payer follow-up. perhaps upside? variant going XX% COVID -- to the year headwinds Omicron of may have in swing I could factor at your guidance? as perhaps XXXX, and as as as point, issue for even key as beyond this be your you through And a the a well discuss in you key Obviously, key that headwinds then the the strong the drivers growth

Peter Greenleaf

Yeah.

physicians' listen, of twofold, excuse heard get it's but think, into offices. or Inclusive companies impacts plenty to have this, of perspective, and patients – it's is, I'm access me, sure one investors our ability Like operating environment, institutions, from their right? today. the other our COVID that, characterize this the way are staff direct obviously, office it to I representatives, physicians it's entire ecosphere, and

the lack of will or impacted. up XXXX into growth to cetera, code importantly, care drop is in visits poll almost new diagnosis books, data on keeping comment, from nephritis, And have ICD-X then And relate they they which fact their picking the in their aggressively my I new for to patients are we that lastly, at and growth how medications, most all least think the in bleed and our at second quoted diagnosis. health et XXXX system, to patient it been XX% showed lupus previously a how

seen so the chemotherapeutic thing And say So point therapies, companies one diagnosis, that, said is even example, direct that just out regimens can't to, why can to other cancer declined. only to thee have cancer have come well. these obviously, numbers adherence who as have we input and been COVID as

anymore, that, belabor factor. won't think that we're out and largest I swing – I moving large, is I some that. by and And one I life really of signs good the because think said, we're that of So seeing as then

drug. because new if one are it time, adhering The patients drug how patients actually least those get our staying actually interesting a to, those or patient of is, and it meaningful cancellations many we've over we therapy forecast at the start do who we me on about start patients were on on discontinuations actually and are our as be how continue approved, second pertains long for as compounds getting fully long the how right the swing and profile. expect to year part now, of to And will we XX% discontinuations and forms. picking forms are patients which is patient big drug, prescription a identify on to know XX% adherence the up staying just And factor said keeping new and in overall It we're can patients to of effect will, this if patients therapy.

data. about So one look more as more we forward to get that, talking we

Ed Arce

question discontinuations. related second Okay. is around All for just then And what you Thanks said, right. that. to

as a to much. mobility later impact X. Phase as XX% on? and Is that if given time, at factoring like think then seems similar well? potential where of to now help to something you're And state? improve may any Thanks Question you've to is – you related line dropped you into that have back You there's or sort some any tracking come may already, steady least you times a XX% of down the your if understand us in could where discontinuations effort off over that I'm is, further as expectations, the it so do of settle that could – said patients couple about that think wondering, or that,

Peter Greenleaf

company hope you. improve upon any view. least data, At trials that that mentioned barring effort least early that number it things from forward. I gives we've safest And new things terms and carrying Two our in first look here, to on We of it a trying the but activity, while know our there, estimate we is see to we've what sort we're probably got it. upon always mindset, report the our tactical of to on to current all we'll the discontinuations, of that Yeah. with at improve you having just to good against seen improvement be to

part centered repeat time? second of The question more was one -- it your around you can

Ed Arce

given Is some doctor Yes, a no all that again it Patients may the with they the to not went and meaningful whatever them to things decided proportion the nothing you maybe have and see that really up to come like of and picking do start just at these program? drop for problem. drug off back. reason,

Peter Greenleaf

align patients ACR off that They on not proteinuria the with many that either prescription these know They there. of length or patients sort do drug. been therapy. fairly back guidelines guidelines are up I cycle the know, What patients activity, once in you silent think control. until seem actual if keep look do And to control, does historical, in polling ULR, miss say on data way as and today, do that is to, CADEGO these the say, have tracking the of here and from is at or on drugs doses surrogate we XXXX all just

for And about coming I miss that seen what think can that's least up is, end back earlier, reason the at a and through the prescription what data. we've to we've talked growth, on patients that

or then Now going how therapy adherence before give data, to think we will we to to think as like. qualify average own that on than time. what adherence therapy I look And see hope said, against I the of of X more need over our our that see X months months is any more steer really we're

data if on some on the put are of drug your is they fallen the reason. patient lost or would question forever back is But a I At up no, think have system? for once least that they that to drug, missed to a the patients seem actively net picking out say prescription physicians

Ed Arce

all. Appreciate Peter. That’s Thanks it.

Operator

Thank you.

Our final question of Martin your this line Please morning comes question. David with from the with Bloom proceed Burton.

David Martin

to last Yes. have question. kind the answered, I a Most have of but been questions my follow-on of

XX%. is to discontinuation the XX% So

are therapy physicians and like payers, You of an kind to But back it sounds not they've physicians on encouraging not would said are us dropped induction I most stay maintenance But off. therapy? the any a it's using as if on. patients but go

Peter Greenleaf

but David, find -- out, At why prescription. Aurinia think might patients be what sort tracking really not picking in Alliance, we will be I that no, through up that would of it least wouldn't their

will and use that not induction we persistency or see we time. more that this you trends us of talk qualitatively is bridging we the That's terms I to in out then the bear to some no telling tell believe as intent an over can one prescriber them think what looking in sort therapy. when I they're is it other of doing. what physicians, the of what to they're

not a a the There host. there's patients or different trend didn't patient And therapy. when patient office I a It's follow on host up didn't of didn't prescription, pick decided either stay the or it through discontinue actual to reasons the everything The from no follow prescription, that there. is consistency therapy, the say one through. couldn't cancel on tolerate of is

Patients sort they host addresses, a of different phone a follow-up. change lost It reasons, number. change of to including is

very and to to to as list So activities compliant that's commercially going that top able way through making work our sure we're we them closely to in track we to can of our need well something be is as down drive. try a efforts continue to of remain

David Martin

your nephritis? one second compared with Okay. starts have drug? treat Benlysta in to and question discontinuations the is, physicians do or decision lupus driving you the nephritis of lupus Thanks. any how my idea of And And other any to what's idea

Peter Greenleaf

tell prescribing data of other The speak they bit they of of challenges. I you is, coding from first higher sort little track, I just the is your to we a what through same always started base. will Difference at and see answer, part but being drugs, hesitate a and again, about

if you treatment think drug. look they they've to getting had codes, back active nephritis long ICD-X approval been tag of the go I and lupus at Benlysta you utilization, before for patients pretty it

of not -- the is my and as patients that them, that's patient I whether stay for question decides a physician TBD. suffering nephritis the to patient a the is that been who've on on this just continue through think, drug but a And for is much review or drug again, the SLE it bout lupus

patient adherence, can we're we at with new what their discontinuation seeing now. right Their see in growth from what line and results least and are

and So from I can not its think do see. what drug population based I

Benlysta. in physicians. that for on and X results How what physicians produced have study little X board. that that's the our a AURORA with And do physicians different is our know patient AURORA versus a drug than we around are in the mind Benlysta resonate making the is continuation a do we've our across drug decision bit But unique messaging know we

for out right what can I here. guidelines of we in the therapy to mean, aligns align what that treatment the they terms see, outcomes. at data treatment from there And are best goals our least directly now, are

got a good position So we we there, think David.

David Martin

Okay. Thanks.

Operator

and participation. question-and-answer and our today. you our your We concludes call for This you. concludes interest session, thus Thank thank

You disconnect lines. your may now

Aurinia Pharmaceuticals (AUPH) 28 Feb 232022 Q4 Earnings call transcript